<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8175">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01835704</url>
  </required_header>
  <id_info>
    <org_study_id>SE-Dnr-2012-446-31M-2</org_study_id>
    <nct_id>NCT01835704</nct_id>
  </id_info>
  <brief_title>Health-economic Evaulation of Interventional Pain Mangement</brief_title>
  <official_title>Health-economic Evaluation of Interventional Pain Management Among Patients With Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eques Indolor AB</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eques Indolor AB</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the cost per QALY (Quality Adjusted life Years) gained all patients that are
      referred to a specialized interventional pain clinic are assessed by Euroqol EQ-5D to
      measure the health-related quality of life at the first visit and then during the following
      year. Quality of life is calculated from EQ-5D by using hte TTO-validated UK-value set. With
      this and calculations of the cost we will be able to calculate the cost per QALY-gained
      which makes it possible to compare interventional pain managment to other treatments for
      pain patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Ecologic or Community, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Quality Adjusted Life gained</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>QALY is calculated from the EQ-5D value using the TTO-validated UK value set accoring to ordinary health-economic evaluations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost per QALY gained</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The cost per QALY gained is calculated according to normal health-economic evaluation models.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Chronic Non-cancer Associated Pain</condition>
  <arm_group>
    <arm_group_label>Chronic pain associated to facet-joints</arm_group_label>
    <description>Patients where the pain can be localized to the facet joints.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic pain of other origin</arm_group_label>
    <description>Patients with pain that can not be localized to facet joints.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Radio-frequency dennervation of facet joint</intervention_name>
    <arm_group_label>Chronic pain associated to facet-joints</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diagnostic nerve-blocks performed under direct x-ray vision</intervention_name>
    <arm_group_label>Chronic pain of other origin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pain of more then 6 months duration
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johan Hambraeus, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Johan Hambraeus, MD</last_name>
    <phone>+46706293798</phone>
    <email>johan@smartkliniken.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Smärtkliniken i Umeå</name>
      <address>
        <city>Umeå</city>
        <zip>90325</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Hambraeus, MD</last_name>
      <phone>+46706293798</phone>
      <email>johan@smartkliniken.eu</email>
    </contact>
    <contact_backup>
      <last_name>Eva Umaerus, RN</last_name>
      <phone>+90186018</phone>
    </contact_backup>
    <investigator>
      <last_name>Johan Hambraeus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fredrik Campbell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 18, 2013</lastchanged_date>
  <firstreceived_date>April 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
